ArticleCureus2025
Challenges and Outcomes of Three Years of the Adhesive Intestinal Obstruction Management Protocol.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSmall bowel obstruction (SBO) is a significant contributor to surgical morbidity, mortality, and healthcare costs, contributing to a significant number of emergency laparotomies. Advancements in diagnostic techniques have improved the accuracy in delineating simple from complicated SBOs. Some adhesive SBOs will ultimately need surgical intervention, mostly when they are complicated cases. Recently, minimally invasive surgeries, enhanced recovery protocols, and multidisciplinary approaches have become more popular in optimising recovery and minimising recurrence risks. On the other hand, most adhesive SBOs can be managed conservatively with bowel rest, nasogastric (NG) decompression, intravenous fluid therapy, and water-soluble oral contrast agents, leading to a significant reduction in operation-related morbidity, hospital stays, and healthcare costs. Current guidelines recommend a trial of conservative management, although not without controversy.
aimThis study aimed to explain the predictive factors of success or failure of treatments of adhesive SBOs and statistically report the effect of co-morbidities and expected outcomes of SBO management, based on three-year data from a single high-volume centre in London, UK. METHODOLOGY: Our retrospective-descriptive study included patients with clinical signs of SBO, older than 16 years old, and CT proving adhesive SBO, who required hospital admission. We excluded patients with other causes of SBO and those who had no CT evidence of adhesive disease. Data were collected from online hospital records and analysed in Microsoft Excel® (Microsoft Corporation, Redmond, Washington). Hospital protocol was NG decompression for at least six hours in uncomplicated cases, followed by oral or NG Gastrografin, with abdominal X-rays taken at six and 12 hours post-Gastrografin intake to assess contrast in the colon or rectum. Successful cases were then given a trial of oral feeds before discharge. Those with no contrast in the large intestine, persistent abdominal pain, and onset abdominal tenderness or peritonitis were taken to surgery. RESULTS AND LIMITATIONS: Out of 415 patients, 30.4% required surgery either as initial mode of treatment or after failed conservative management, proving the effectivity of therapeutic Gastrografin (69.6%), followed by 35.2% being 75 or less years old, proving SBO is more prevalent in elderly population with co-morbidities, as 40.5% are ASA Grade 3, prone to post-operative complications. Surprisingly, COPD patients required surgery more often than those who did not have it, as they desaturate due to distension easily. On the other hand, not much statistical difference is seen in the 30-day mortality rate between the operated and conservatively managed groups.
conclusionOur study aligns with the literature to prove that our management protocol is safe. Alongside, the post-operative burden of those undergoing surgery is high; it is vital to identify complex patients for surgery to reduce mortality and morbidity. This goes hand in hand with weighing risks and benefits. Elderly patients carry the risk of major complications plus a higher mortality rate. Timely intervention with therapeutic Gastrografin can minimise the hospital stay and the costs for the NHS owing to long stay post-operatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.